<DOC>
	<DOCNO>NCT00446459</DOCNO>
	<brief_summary>This 12-month , phase II , prospective , open label study , evaluate effect mycophenolate mofetil ( MMF ) among patient kidney transplant list high Panel Reactive Antibody ( PRA ) level . On average , increase PRA 0 50 % specifically Washington Organ Procurement Organization ( OPO ) increase wait time 3 6 year . Spontaneous decrease PRA rarely occur associate decreased chance transplantation decrease rate survival .</brief_summary>
	<brief_title>Effects Mycophenolate Mofetil ( MMF ) On Anti-HLA ( Human Leukocyte Antigen ) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant .</brief_title>
	<detailed_description>HYPOTHESIS : mycophenolate mofetil give 8 month highly sensitized subject await kidney transplant , result decrement PRA 10 % approximately 40 % patient . This decrement allow improve rate transplantation . BACKGROUND : Patients expose human tissue prior transplant , blood transfusion pregnancy may develop anti-bodies 'cell marker human white blood cell ' call 'Human Leukocyte Antigens ' ( HLA ) . Preformed anti-bodies foreign human tissue call SENSITIZATION . Sensitized patient likely reject kidney donor possess antigenic profile already sensitize . This limit recipient 's possible donor pool general population . The Panel Reactive Antibodies ( PRA ) test panel represent HLA antigenic profile local community . The test panel use measure recipient 's reactivity ( percent ) variety HLA antigens . A PRA 75 % mean patient react 75 % antigens test panel . A PRA panel great 50 % indicate subject ( potential organ recipient ) already significant number antibody pre-formed human tissue highly sensitize . Spontaneous decrease PRA titer rarely occur thus probability transplantation sensitize patient significantly decrease . STUDY POPULATION : adult University Washington Medical Center patient , kidney transplant wait list currently receive dialysis PRA level 50 % period 6 month longer . TREATMENT PLAN/ INTERVENTION : CONSENT : Consent obtain subject . SCREENING : Prior start MMF , thorough medical history physical exam obtain . Patients screen clinically occurrence infection protective antibody response prior vaccination assure date immunization . INVESTIGATIONAL PRODUCT : Mycophenolate mofetil ( MMF ) use routine therapy prevention rejection transplant recipient also use routinely treatment autoimmune disease primary renal disease IgA nephropathy lupus nephritis . HOFFMANN LA ROCHE : Will provide Mycophenolate mofetil , MMF CellCept well cost laboratory test . DOSAGE AND ADMINISTRATION : MMF dispense investigational drug pharmacist 250mg capsule , take orally twice daily . Dosing MMF begin 500 mg bid 30 day increase 1 gm bid subject experience undo gastrointestinal side effect decrease WBC . STUDY DESIGN : The subject continually evaluate 12 month . Month 4 : If subject 's PRA drop 10 % month 4 , subject remain MMF without change . If subject 's PRA NOT drop 10 % month four infection NOT occur , subject remain MMF increase dosage possible . If month four , 4 serious infection occur MMF dose reduce stopped subject . If stop follow 4 month . Month 8 : If subject 's PRA NOT drop 10 % month 8 , MMF discontinue subject follow next 4 month month 12 post enrollment . If subject 's PRA DOES drop 10 % month 8 NO infection ( ) occur , subject continue MMF month 12 . Study subject follow maximum 12 month . OBJECTIVES : The primary endpoint : 1 ) The number subject achieve PRA reduction 10 % great within 8 month initiate mycophenolate mofetil ( MMF ) therapy . The secondary outcome measure include : 1 . The number subject receive transplant study , 2 . The number subject experience Institutional Review Board ( IRB ) reportable infection , 3 . The number subject 's white blood cell count ( WBC ) Immunoglobulin G M ( IgG/ IgM ) titer range , 4 . The number transplant negative crossmatch . CLINICAL AND LABORATORY EVALUATIONS : LAB ASSESSMENT : Immunology : PRA ( panel reactive antibody ) take monthly level individual HLA anti-bodies evaluate every month . Safety : Total level Immunoglobulin G ( IgG ) Immunoglobulin M ( IgM ) , measure indigenous anti-body population level . As well HepB surface Antibody CMV test do monitor screen change health subject 's immune system ie . loss memory immunization . A complete blood count ( CBC ) take visit screen anemia . Differential analysis CBD screen platelet reduction possible bone marrow suppression . The subject 's CBC check frequently his/her WBC , hematocrit platelet low . Subjects follow closely 12 month .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Hypertension , Renal</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Persons kidney transplant wait list currently receive hemodialysis Age range 18 75 Outpatient status Patients PRA 50 % 6 month Patients updated immunization tetanus , influenza , hepatitis B , pneumococcus Patients PPD ( purify protein derivative ) test within last 6 month . If subject prior history TB ( tuberculosis ) positive PPD , documentation adequate treatment require . Women childbearing potential must negative serum pregnancy test prior enrol study agree use medically acceptable method contraception throughout study . Active infection History multiple recurrent infection define 3 urinary tract infection , 2 episode pneumonia 3 episode otitis/sinusitis one year , two dialysis line peritoneal infection within one year . Infection HCV ( hepatitis C virus ) HBV ( hepatitis B virus ) HIV ( human immunodeficiency virus ) . Lack documentation PPD test Lack documentation treatment positive PPD Pregnant breastfeed Baseline leukopenia , WBC &lt; 4.0 Thrombocytopenia ( platelet count &lt; 130 ) difficult treat anemia , HCT chronically &lt; 32 intravenous iron EPO ( erythropoietin ) therapy Transfusion within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>CellCept</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Kidney</keyword>
	<keyword>Renal</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>Glomerulonephropathy</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Allograft</keyword>
	<keyword>Compatibility</keyword>
	<keyword>HLA</keyword>
	<keyword>PRA</keyword>
	<keyword>Transplant</keyword>
	<keyword>Sensitization</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Transplantation , Kidney</keyword>
</DOC>